Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations

about

Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations

Item

http://www.wikidata.org/entity/Q59085289

description

article publié dans la revue scientifique Nature

@fr

scientific article published in Nature

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована в Nature в липні 2018

@uk

name

Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations

@en

Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations

@nl

type

Item

label

Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations

@en

Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations

@nl

prefLabel

Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations

@en

Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations

@nl

P1476

Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations

@en

P2093

Abbas Nazir

http://www.w3.org/2001/XMLSchema#string

Alan H Shih

http://www.w3.org/2001/XMLSchema#string

Andrew M Intlekofer

http://www.w3.org/2001/XMLSchema#string

Ariën S Rustenburg

http://www.w3.org/2001/XMLSchema#string

Bin Wu

http://www.w3.org/2001/XMLSchema#string

Bo Wang

http://www.w3.org/2001/XMLSchema#string

Christopher Famulare

http://www.w3.org/2001/XMLSchema#string

Craig B Thompson

http://www.w3.org/2001/XMLSchema#string

Eytan M Stein

http://www.w3.org/2001/XMLSchema#string

Fabian M Correa

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate

DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation

A hierarchical approach to all-atom protein loop prediction

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

P2888

s41586-018-0251-7

P304

125-129

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/S41586-018-0251-7

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

7712

http://www.w3.org/2001/XMLSchema#string

P478

559

http://www.w3.org/2001/XMLSchema#string

P50

Elli Papaemmanuil

Gregory Petsko

Martin S Tallman

P577

2018-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29950729

http://www.w3.org/2001/XMLSchema#string

P932

6121718

http://www.w3.org/2001/XMLSchema#string